Katsuya Komatsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katsuya Komatsu has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Takeshi Mikami
Department of Neurosurgery, Sapporo Medical University, Sapporo, Japan
12 shared publications Nobuhiro Mikuni
Department of Neurosurgery, Sapporo Medical University, Japan; and
11 shared publications- Nobuhiro Mikuni
Department of Neurosurgery, Sapporo Medical University, Sapporo, Hokkaido, Japan
10 shared publications - Masahiko Wanibuchi
Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan
8 shared publications Yukinori Akiyama
Department of Neurosurgery, Sapporo Medical University, Japan; and
8 shared publications- Kei Miyata
Department of Neurosurgery, Sapporo Medical University, Sapporo, Japan
7 shared publications
Latest Publications
- 10 November 2026
- Published byĀ Wolters Kluwer HealthĀ inĀ Neurology
- Vol.Ā 107 Ā (9)
Bilateral Anomalous Ophthalmic Artery Course With an Internal Carotid Artery Configuration Mimicking Moyamoya Angiopathy
- 10 November 2026
- Published byĀ Wolters Kluwer HealthĀ inĀ Neurology
- Vol.Ā 107 Ā (9)
Bilateral Anomalous Ophthalmic Artery Course With an Internal Carotid Artery Configuration Mimicking Moyamoya Angiopathy
- Open Access
- 25 May 2026
- Published byĀ Journal of Neurosurgery Publishing Group (JNSPG)Ā inĀ Journal of Neurosurgery: Case Lessons
- Vol.Ā 11 Ā (21)
Stent-assisted coil embolization for a graft-related aneurysm following high-flow bypass: illustrative case
BACKGROUND: High-flow bypass (HFB) combined with parent artery occlusion is an established treatment for complex cerebral aneurysms. Graft-related aneurysm (GA) at the anastomotic site is a rare late complication of HFB, and its optimal management remains poorly defined. The authors report a case of an unruptured GA that enlarged more than 10 years after HFB and was treated with stent-assisted coil embolization (SACE). OBSERVATIONS: A 50-year-old woman had undergone HFB using a radial artery (RA) graft for a cavernous segment aneurysm of the internal carotid artery 10 years earlier. A small aneurysmal dilation at the anastomosis was detected 2 years postoperatively, but long-term follow-up was interrupted. Ten years after the initial surgery, imaging revealed enlargement of a saccular GA with a bleb at the anastomotic site. SACE was performed through the tortuous RA graft using a distal access catheter for stable support, with deployment of an intracranial stent across the anastomosis to secure coil stability. Complete aneurysm occlusion was achieved without procedural complications. Follow-up cerebral angiography confirmed durable occlusion with preserved bypass patency. LESSONS: GA can occur as a late complication after HFB, underscoring the importance of long-term follow-up and medical management. Endovascular treatment may represent a less invasive treatment option in selected cases. https://thejns.org/doi/10.3171/CASE26249
- 25 May 2026
- Published byĀ Journal of Neurosurgery Publishing Group (JNSPG)Ā inĀ Journal of Neurosurgery: Case Lessons
- Vol.Ā 11 Ā (21)
Open AccessStent-assisted coil embolization for a graft-related aneurysm following high-flow bypass: illustrative case
BACKGROUND: High-flow bypass (HFB) combined with parent artery occlusion is an established treatment for complex cerebral aneurysms. Graft-related aneurysm (GA) at the anastomotic site is a rare late complication of HFB, and its optimal management remains poorly defined. The authors report a case of an unruptured GA that enlarged more than 10 years after HFB and was treated with stent-assisted coil embolization (SACE). OBSERVATIONS: A 50-year-old woman had undergone HFB using a radial artery (RA) graft for a cavernous segment aneurysm of the internal carotid artery 10 years earlier. A small aneurysmal dilation at the anastomosis was detected 2 years postoperatively, but long-term follow-up was interrupted. Ten years after the initial surgery, imaging revealed enlargement of a saccular GA with a bleb at the anastomotic site. SACE was performed through the tortuous RA graft using a distal access catheter for stable support, with deployment of an intracranial stent across the anastomosis to secure coil stability. Complete aneurysm occlusion was achieved without procedural complications. Follow-up cerebral angiography confirmed durable occlusion with preserved bypass patency. LESSONS: GA can occur as a late complication after HFB, underscoring the importance of long-term follow-up and medical management. Endovascular treatment may represent a less invasive treatment option in selected cases. https://thejns.org/doi/10.3171/CASE26249
- 31 May 2022
- Published byĀ ElsevierĀ inĀ Journal of Stroke and Cerebrovascular Diseases
- Vol.Ā 31 Ā (8) , 106584
Validity of Preoperative Screening Before Open-Heart Surgery in Reduction of Perioperative Ischemic Stroke
- 31 May 2022
- Published byĀ ElsevierĀ inĀ Journal of Stroke and Cerebrovascular Diseases
- Vol.Ā 31 Ā (8) , 106584
Validity of Preoperative Screening Before Open-Heart Surgery in Reduction of Perioperative Ischemic Stroke
- 1 February 2022
- Published byĀ S. Karger AGĀ inĀ Cerebrovascular Diseases
- Vol.Ā 51 Ā (4) , 413-426
Macrohistory of Moyamoya Disease Analyzed Using Artificial Intelligence
Introduction: Moyamoya disease is characterized by progressive stenotic changes in the terminal segment of the internal carotid artery and the development of abnormal vascular networks called moyamoya vessels. The objective of this review was to provide a holistic view of the epidemiology, etiology, clinical findings, treatment, and pathogenesis of moyamoya disease. A literature search was performed in PubMed using the term āmoyamoya disease,ā for articles published until 2021. Results: Artificial intelligence (AI) clustering was used to classify the articles into 5 clusters: (1) pathophysiology (23.5%); (2) clinical background (37.3%); (3) imaging (13.2%); (4) treatment (17.3%); and (5) genetics (8.7%). Many articles in the āclinical backgroundā cluster were published from the 1970s. However, in the ātreatmentā and āgeneticsā clusters, the articles were published from the 2010s through 2021. In 2011, it was confirmed that a gene called Ringin protein 213 (RNF213) is a susceptibility gene for moyamoya disease. Since then, tremendous progress in genomic, transcriptomic, and epigenetic profiling (e.g., methylation profiling) has resulted in new concepts for classifying moyamoya disease. Our literature survey revealed that the pathogenesis involves aberrations of multiple signaling pathways through genetic mutations and altered gene expression. Conclusion: We analyzed the content vectors in abstracts using AI, and reviewed the pathophysiology, clinical background, radiological features, treatments, and genetic peculiarity of moyamoya disease.
- 1 February 2022
- Published byĀ S. Karger AGĀ inĀ Cerebrovascular Diseases
- Vol.Ā 51 Ā (4) , 413-426
Macrohistory of Moyamoya Disease Analyzed Using Artificial Intelligence
Introduction: Moyamoya disease is characterized by progressive stenotic changes in the terminal segment of the internal carotid artery and the development of abnormal vascular networks called moyamoya vessels. The objective of this review was to provide a holistic view of the epidemiology, etiology, clinical findings, treatment, and pathogenesis of moyamoya disease. A literature search was performed in PubMed using the term āmoyamoya disease,ā for articles published until 2021. Results: Artificial intelligence (AI) clustering was used to classify the articles into 5 clusters: (1) pathophysiology (23.5%); (2) clinical background (37.3%); (3) imaging (13.2%); (4) treatment (17.3%); and (5) genetics (8.7%). Many articles in the āclinical backgroundā cluster were published from the 1970s. However, in the ātreatmentā and āgeneticsā clusters, the articles were published from the 2010s through 2021. In 2011, it was confirmed that a gene called Ringin protein 213 (RNF213) is a susceptibility gene for moyamoya disease. Since then, tremendous progress in genomic, transcriptomic, and epigenetic profiling (e.g., methylation profiling) has resulted in new concepts for classifying moyamoya disease. Our literature survey revealed that the pathogenesis involves aberrations of multiple signaling pathways through genetic mutations and altered gene expression. Conclusion: We analyzed the content vectors in abstracts using AI, and reviewed the pathophysiology, clinical background, radiological features, treatments, and genetic peculiarity of moyamoya disease.
- 1 October 2021
- Published byĀ ElsevierĀ inĀ Clinical Neurophysiology
- Vol.Ā 132 Ā (10) , 2351-2356
Effects of polarity of bipolar sensorimotor direct cortical stimulation on intraoperative motor evoked potentials
- 1 October 2021
- Published byĀ ElsevierĀ inĀ Clinical Neurophysiology
- Vol.Ā 132 Ā (10) , 2351-2356
Effects of polarity of bipolar sensorimotor direct cortical stimulation on intraoperative motor evoked potentials
- 1 August 2021
- Published byĀ ElsevierĀ inĀ Journal of Stroke and Cerebrovascular Diseases
- Vol.Ā 30 Ā (8) , 105852
Additional Revascularization Using Multiple Burr Holes for PCA Involvement in Moyamoya Disease
- 1 August 2021
- Published byĀ ElsevierĀ inĀ Journal of Stroke and Cerebrovascular Diseases
- Vol.Ā 30 Ā (8) , 105852
Additional Revascularization Using Multiple Burr Holes for PCA Involvement in Moyamoya Disease
- 1 January 2021
- Published byĀ ElsevierĀ inĀ Journal of Stroke and Cerebrovascular Diseases
- Vol.Ā 30 Ā (1) , 105450
Preoperatively estimated graft flow rate contributes to the improvement of hemodynamics in revascularization for Moyamoya disease
- 1 January 2021
- Published byĀ ElsevierĀ inĀ Journal of Stroke and Cerebrovascular Diseases
- Vol.Ā 30 Ā (1) , 105450
Preoperatively estimated graft flow rate contributes to the improvement of hemodynamics in revascularization for Moyamoya disease
- Open Access
- 5 November 2020
- Published byĀ Springer NatureĀ inĀ BMC Neurology
- Vol.Ā 20 Ā (1) , 1-9
Changes in treatment strategy over time for arteriovenous malformation in a Japanese high-volume center
Background: Despite rapid developments in devices used to treat arteriovenous malformation (AVM), a randomised trial of Unruptured Brain Arteriovenous malformations published in 2014 recommended conservative treatment for nonhemorrhagic AVM. The purpose of the current retrospective study was to confirm how AVM treatment in Japan has changed and to assess the safety of treatment for hemorrhagic and nonhemorrhagic AVMs. Methods: We enrolled 242 consecutive patients with AVM; each patientās treatment was selected and performed at our hospital. The type of onset, SpetzlerāMartin (SāM) grade, age, sex, selected treatment, mortality, and morbidity were compared between the first and second periods of our study. Results: In patients with grade IāIII AVM, the selected treatment changed between the first and second periods; however, in grade IV and V patients, the selected treatment did not change. Overall, interventions by microsurgery alone decreased (p < 0.001), the proportion of total treatments including microsurgery decreased (p = 0.005), interventions using stereotactic radiosurgery (SRS) alone increased (p = 0.009), and interventions including SRS increased (p = 0.002). Morbidity associated with intervention was 0.92% in the first period and 0% in the second period, and mortality was 0.92% in the first period and 1.67% in the second. Conclusions: With the development of new devices, the selected treatment was changed in patients with SāM grade IāIII AVM, but was not changed in patients with grade IV and V. The complication rate was low and did not change throughout the periods. These findings suggest that the safety of treatment depends on a full understanding of device development and the selection of proper treatment, not on hemorrhagic onset. Further treatment innovations are expected to change the treatment for grade IV and V AVMs.
- 5 November 2020
- Published byĀ Springer NatureĀ inĀ BMC Neurology
- Vol.Ā 20 Ā (1) , 1-9
Open AccessChanges in treatment strategy over time for arteriovenous malformation in a Japanese high-volume center
Background: Despite rapid developments in devices used to treat arteriovenous malformation (AVM), a randomised trial of Unruptured Brain Arteriovenous malformations published in 2014 recommended conservative treatment for nonhemorrhagic AVM. The purpose of the current retrospective study was to confirm how AVM treatment in Japan has changed and to assess the safety of treatment for hemorrhagic and nonhemorrhagic AVMs. Methods: We enrolled 242 consecutive patients with AVM; each patientās treatment was selected and performed at our hospital. The type of onset, SpetzlerāMartin (SāM) grade, age, sex, selected treatment, mortality, and morbidity were compared between the first and second periods of our study. Results: In patients with grade IāIII AVM, the selected treatment changed between the first and second periods; however, in grade IV and V patients, the selected treatment did not change. Overall, interventions by microsurgery alone decreased (p < 0.001), the proportion of total treatments including microsurgery decreased (p = 0.005), interventions using stereotactic radiosurgery (SRS) alone increased (p = 0.009), and interventions including SRS increased (p = 0.002). Morbidity associated with intervention was 0.92% in the first period and 0% in the second period, and mortality was 0.92% in the first period and 1.67% in the second. Conclusions: With the development of new devices, the selected treatment was changed in patients with SāM grade IāIII AVM, but was not changed in patients with grade IV and V. The complication rate was low and did not change throughout the periods. These findings suggest that the safety of treatment depends on a full understanding of device development and the selection of proper treatment, not on hemorrhagic onset. Further treatment innovations are expected to change the treatment for grade IV and V AVMs.
- Open Access
- 2 November 2020
- Published byĀ Springer NatureĀ inĀ Research Square
Changes in treatment strategy over time for arteriovenous malformation in a Japanese high-volume center
Background: Despite rapid developments in devices used to treat arteriovenous malformation (AVM), a randomised trial of Unruptured Brain Arteriovenous malformations published in 2014 recommended conservative treatment for nonhemorrhagic AVM. The purpose of the current retrospective study was to confirm how AVM treatment in Japan has changed and to assess the safety of treatment for hemorrhagic and nonhemorrhagic AVMs.Methods: We enrolled 242 consecutive patients with AVM; each patientās treatment was selected and performed at our hospital. The type of onset, SpetzlerāMartin (SāM) grade, age, sex, selected treatment, mortality, and morbidity were compared between the first and second periods of our study.Results: In patients with grade IāIII AVM, the selected treatment changed between the first and second periods; however, in grade IV and V patients, the selected treatment did not change. Overall, interventions by microsurgery alone decreased (p < 0.001), the proportion of total treatments including microsurgery decreased (p = 0.005), interventions using stereotactic radiosurgery (SRS) alone increased (p = 0.009), and interventions including SRS increased (p = 0.002). Morbidity associated with intervention was 0.92% in the first period and 0% in the second period, and mortality was 0.92% in the first period and 1.67% in the second. Conclusions: With the development of new devices, the selected treatment was changed in patients with SāM grade IāIII AVM, but was not changed in patients with grade IV and V. The complication rate was low and did not change throughout the periods. These findings suggest that the safety of treatment depends on a full understanding of device development and the selection of proper treatment, not on hemorrhagic onset. Further treatment innovations are expected to change the treatment for grade IV and V AVMs.
- 2 November 2020
- Published byĀ Springer NatureĀ inĀ Research Square
Open AccessChanges in treatment strategy over time for arteriovenous malformation in a Japanese high-volume center
Background: Despite rapid developments in devices used to treat arteriovenous malformation (AVM), a randomised trial of Unruptured Brain Arteriovenous malformations published in 2014 recommended conservative treatment for nonhemorrhagic AVM. The purpose of the current retrospective study was to confirm how AVM treatment in Japan has changed and to assess the safety of treatment for hemorrhagic and nonhemorrhagic AVMs.Methods: We enrolled 242 consecutive patients with AVM; each patientās treatment was selected and performed at our hospital. The type of onset, SpetzlerāMartin (SāM) grade, age, sex, selected treatment, mortality, and morbidity were compared between the first and second periods of our study.Results: In patients with grade IāIII AVM, the selected treatment changed between the first and second periods; however, in grade IV and V patients, the selected treatment did not change. Overall, interventions by microsurgery alone decreased (p < 0.001), the proportion of total treatments including microsurgery decreased (p = 0.005), interventions using stereotactic radiosurgery (SRS) alone increased (p = 0.009), and interventions including SRS increased (p = 0.002). Morbidity associated with intervention was 0.92% in the first period and 0% in the second period, and mortality was 0.92% in the first period and 1.67% in the second. Conclusions: With the development of new devices, the selected treatment was changed in patients with SāM grade IāIII AVM, but was not changed in patients with grade IV and V. The complication rate was low and did not change throughout the periods. These findings suggest that the safety of treatment depends on a full understanding of device development and the selection of proper treatment, not on hemorrhagic onset. Further treatment innovations are expected to change the treatment for grade IV and V AVMs.
- 1 October 2020
- Published byĀ ElsevierĀ inĀ World Neurosurgery
- Vol.Ā 142, e58-e65
Recurrence Interval Within 1 Year Leads to Death in Patients with Grade 2 Meningioma
- 1 October 2020
- Published byĀ ElsevierĀ inĀ World Neurosurgery
- Vol.Ā 142, e58-e65
Recurrence Interval Within 1 Year Leads to Death in Patients with Grade 2 Meningioma